{"id": "article-133043_0", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction", "content": "This article is made available for historical review, monoclonal antibody use is not currently indicated for this condition.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction. This article is made available for historical review, monoclonal antibody use is not currently indicated for this condition."}
{"id": "article-133043_1", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction", "content": "Coronavirus disease 2019 (COVID-19) pandemic has impacted\u00a0the world tremendously since the first cases were identified in 2019. COVID-19 was rapidly disseminated globally, with infections identified in most world societies within the first few months of 2020. COVID-19, the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had devastating effects on public health and the world economy. In the United States, the earliest and most well-documented areas impacted were large cities and urban communities. Initial efforts to curb the transmission of COVID-19 were largely successful in helping stem continued widespread transmission. As vaccinations for COVID-19 began rollout, authorities eased some of the initial transmission mitigation strategies, and coupled with the increased prominence of COVID-19 variant strains, transmission and infection rates saw an increase throughout the spring and summer of 2021.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction. Coronavirus disease 2019 (COVID-19) pandemic has impacted\u00a0the world tremendously since the first cases were identified in 2019. COVID-19 was rapidly disseminated globally, with infections identified in most world societies within the first few months of 2020. COVID-19, the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had devastating effects on public health and the world economy. In the United States, the earliest and most well-documented areas impacted were large cities and urban communities. Initial efforts to curb the transmission of COVID-19 were largely successful in helping stem continued widespread transmission. As vaccinations for COVID-19 began rollout, authorities eased some of the initial transmission mitigation strategies, and coupled with the increased prominence of COVID-19 variant strains, transmission and infection rates saw an increase throughout the spring and summer of 2021."}
{"id": "article-133043_2", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction", "content": "Despite their lower population density, rural and underserved areas continue to be especially vulnerable to poor outcomes from SARS-CoV-2. The disparity in healthcare outcomes in\u00a0these\u00a0areas is multifactorial. In general, rural and underserved\u00a0healthcare infrastructure is less developed than its urban counterparts. [1] These residents often have significantly increased distances\u00a0to travel to access advanced health care facilities. The travel gap often leads to residents not seeking care until the disease has reached advanced stages. Concerning rural and underserved patients, this distance affects all diseases, with cancer often being found after metastasis, diabetes after end-organ dysfunction, hypertension after a stroke or heart attack, and COVID-19 after pneumonia and subsequent hypoxia develop. Additionally, in rural and underserved areas, patient demographics (i.e., tobacco use, hypertension, diabetes, obesity, and older age) often\u00a0fall in categories associated with a higher risk of mortality and morbidity from SARS-CoV-2 infection.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction. Despite their lower population density, rural and underserved areas continue to be especially vulnerable to poor outcomes from SARS-CoV-2. The disparity in healthcare outcomes in\u00a0these\u00a0areas is multifactorial. In general, rural and underserved\u00a0healthcare infrastructure is less developed than its urban counterparts. [1] These residents often have significantly increased distances\u00a0to travel to access advanced health care facilities. The travel gap often leads to residents not seeking care until the disease has reached advanced stages. Concerning rural and underserved patients, this distance affects all diseases, with cancer often being found after metastasis, diabetes after end-organ dysfunction, hypertension after a stroke or heart attack, and COVID-19 after pneumonia and subsequent hypoxia develop. Additionally, in rural and underserved areas, patient demographics (i.e., tobacco use, hypertension, diabetes, obesity, and older age) often\u00a0fall in categories associated with a higher risk of mortality and morbidity from SARS-CoV-2 infection."}
{"id": "article-133043_3", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction", "content": "From a resource standpoint, rural areas have limited availability of intensive care unit (ICU) beds, ventilators, and access to novel medications through clinical trials. Furthermore, rural communities have always been especially vulnerable to supply chain disruptions, and the\u00a0COVID-19\u00a0pandemic exposed some\u00a0fragilities in our national supply chain.\u00a0A nationwide shortage of personal protective equipment (PPE), testing devices (e.g., nasopharyngeal swabs, reagents, and test kits), and respiratory ventilators plagued initial efforts to combat COVID-19. [2] The acute shortage of testing devices made it neither practical nor beneficial to promote universal screening for COVID-19 in rural areas. Perhaps even more disparate, as a country,\u00a0the USA is experiencing a shortage of trained nurses, allied health providers, and physicians, and\u00a0rural communities are often the most challenged in providing adequate numbers of health care professionals and, in particular, sub-specialist physicians to care for their residents. [3]", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction. From a resource standpoint, rural areas have limited availability of intensive care unit (ICU) beds, ventilators, and access to novel medications through clinical trials. Furthermore, rural communities have always been especially vulnerable to supply chain disruptions, and the\u00a0COVID-19\u00a0pandemic exposed some\u00a0fragilities in our national supply chain.\u00a0A nationwide shortage of personal protective equipment (PPE), testing devices (e.g., nasopharyngeal swabs, reagents, and test kits), and respiratory ventilators plagued initial efforts to combat COVID-19. [2] The acute shortage of testing devices made it neither practical nor beneficial to promote universal screening for COVID-19 in rural areas. Perhaps even more disparate, as a country,\u00a0the USA is experiencing a shortage of trained nurses, allied health providers, and physicians, and\u00a0rural communities are often the most challenged in providing adequate numbers of health care professionals and, in particular, sub-specialist physicians to care for their residents. [3]"}
{"id": "article-133043_4", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction", "content": "SARS-CoV-2 primarily affects the respiratory system, with most transmission occurring from close contact with pre-symptomatic, asymptomatic, or symptomatic carriers. Since the declaration of COVID-19 as a global pandemic by the World Health Organization (WHO), considerable progress has been made in managing COVID-19 with the development of novel therapeutics and efficacious vaccines that have led to favorable patient outcomes and has helped limit the spread of the virus. A variety of therapeutic options are currently available in the management of COVID-19, including antiviral medications, monoclonal antibodies, and immunomodulatory agents. However, the therapeutic potential and clinical use of these drugs are limited and are specific to the stage of the illness. Further, rural areas have limited resources to provide access to monoclonal antibody therapy. Some strategies to provide options for rural healthcare systems will be discussed here.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction. SARS-CoV-2 primarily affects the respiratory system, with most transmission occurring from close contact with pre-symptomatic, asymptomatic, or symptomatic carriers. Since the declaration of COVID-19 as a global pandemic by the World Health Organization (WHO), considerable progress has been made in managing COVID-19 with the development of novel therapeutics and efficacious vaccines that have led to favorable patient outcomes and has helped limit the spread of the virus. A variety of therapeutic options are currently available in the management of COVID-19, including antiviral medications, monoclonal antibodies, and immunomodulatory agents. However, the therapeutic potential and clinical use of these drugs are limited and are specific to the stage of the illness. Further, rural areas have limited resources to provide access to monoclonal antibody therapy. Some strategies to provide options for rural healthcare systems will be discussed here."}
{"id": "article-133043_5", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction", "content": "The pathogenesis of COVID-19 illness occurs in two distinct phases, an early stage characterized by profound SARS-CoV-2 viral replication followed by a late phase characterized by a hyperinflammatory state induced by the release of cytokines such as tumor necrosis factor-\u03b1 (TNF \u03b1), granulocyte-macrophage colony-stimulating factor (GM-CSF), Interleukin-1 (IL-1), IL-6, interferon (IFN)-\u03b3, and activation of the coagulation system resulting in a prothrombotic state. Antiviral therapy and antibody-based treatments are likely to be more effective if used during the early phase of the illness. Immunomodulating therapies, either alone or in combination with antiviral and antibody-based therapies, may be more effective when used in the later stage to combat the cytokine-mediated hyperinflammatory state that causes severe illness. [4]", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction. The pathogenesis of COVID-19 illness occurs in two distinct phases, an early stage characterized by profound SARS-CoV-2 viral replication followed by a late phase characterized by a hyperinflammatory state induced by the release of cytokines such as tumor necrosis factor-\u03b1 (TNF \u03b1), granulocyte-macrophage colony-stimulating factor (GM-CSF), Interleukin-1 (IL-1), IL-6, interferon (IFN)-\u03b3, and activation of the coagulation system resulting in a prothrombotic state. Antiviral therapy and antibody-based treatments are likely to be more effective if used during the early phase of the illness. Immunomodulating therapies, either alone or in combination with antiviral and antibody-based therapies, may be more effective when used in the later stage to combat the cytokine-mediated hyperinflammatory state that causes severe illness. [4]"}
{"id": "article-133043_6", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction", "content": "Individuals of all ages are at risk for infection and severe disease. However, as noted previously, high-risk individuals are those aged \u226560 years and with underlying medical comorbidities (obesity, cardiovascular disease, chronic kidney disease, diabetes, chronic lung disease, smoking, cancer, solid organ or hematopoietic stem cell transplant recipients) are at increased risk of developing severe COVID-19 infection. The percentage of COVID-19 patients requiring hospitalization was six times higher in those with preexisting medical conditions than those without medical conditions (45.4% vs. 7.6%) based on an analysis by Stokes et al. of confirmed cases reported to the CDC during January 22\u00a0to May 30, 2020. [5]", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction. Individuals of all ages are at risk for infection and severe disease. However, as noted previously, high-risk individuals are those aged \u226560 years and with underlying medical comorbidities (obesity, cardiovascular disease, chronic kidney disease, diabetes, chronic lung disease, smoking, cancer, solid organ or hematopoietic stem cell transplant recipients) are at increased risk of developing severe COVID-19 infection. The percentage of COVID-19 patients requiring hospitalization was six times higher in those with preexisting medical conditions than those without medical conditions (45.4% vs. 7.6%) based on an analysis by Stokes et al. of confirmed cases reported to the CDC during January 22\u00a0to May 30, 2020. [5]"}
{"id": "article-133043_7", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction", "content": "An encouraging approach to address the COVID-19 associated mortality and preventing the increased utilization of healthcare resources is by terminating the progression of viral replication preventing the progression to the hyperinflammatory stage of COVID-19, which causes severe illness in high-risk non-hospitalized patients. Initially, the focus of treatment was directed mainly towards hospitalized patients with COVID-19 illness. However, the clinical focus over the course of the pandemic expanded towards combatting the illness early on by reducing the viral load in patients with early disease, thus attempting to halt the disease progression. Monoclonal antibodies targeting the spike protein of the SARS-CoV-2 have yielded positive in vitro results. [6] [7] They are considered a promising approach in managing non-hospitalized patients with mild to moderate COVID-19 who are at high risk of developing severe illness.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction. An encouraging approach to address the COVID-19 associated mortality and preventing the increased utilization of healthcare resources is by terminating the progression of viral replication preventing the progression to the hyperinflammatory stage of COVID-19, which causes severe illness in high-risk non-hospitalized patients. Initially, the focus of treatment was directed mainly towards hospitalized patients with COVID-19 illness. However, the clinical focus over the course of the pandemic expanded towards combatting the illness early on by reducing the viral load in patients with early disease, thus attempting to halt the disease progression. Monoclonal antibodies targeting the spike protein of the SARS-CoV-2 have yielded positive in vitro results. [6] [7] They are considered a promising approach in managing non-hospitalized patients with mild to moderate COVID-19 who are at high risk of developing severe illness."}
{"id": "article-133043_8", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction", "content": "Monoclonal antibodies (mAbs) are immune system proteins developed from a single cell lineage that demonstrate a high affinity for their target cell. Monoclonal antibodies were first developed by K\u00f6hler and Milstein in 1975 using hybridoma technology. [8] Since then, research has made significant progress in the molecular engineering world that has enabled the establishment of monoclonal antibodies as targeted therapies in various neoplastic conditions, autoimmune, post-transplant immunosuppression, and infectious diseases. [9] When used as antiviral therapies, neutralizing antibodies play an indispensable part in achieving passive antiviral immunity and are also instrumental in preventing or regulating many viral illnesses.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction. Monoclonal antibodies (mAbs) are immune system proteins developed from a single cell lineage that demonstrate a high affinity for their target cell. Monoclonal antibodies were first developed by K\u00f6hler and Milstein in 1975 using hybridoma technology. [8] Since then, research has made significant progress in the molecular engineering world that has enabled the establishment of monoclonal antibodies as targeted therapies in various neoplastic conditions, autoimmune, post-transplant immunosuppression, and infectious diseases. [9] When used as antiviral therapies, neutralizing antibodies play an indispensable part in achieving passive antiviral immunity and are also instrumental in preventing or regulating many viral illnesses."}
{"id": "article-133043_9", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction", "content": "Over the years, passive immunization against many viral diseases was achieved by administering polyclonal sera obtained from convalescent human donors or animals. However, polyclonal antibody preparations are increasingly being replaced by monoclonal antibodies by virtue of their favorable safety profile and target specificity when used in different viral diseases. [10] Palivizumab was the first antiviral monoclonal antibody approved by the US Food and Drug Administration (FDA) for prophylaxis of respiratory syncytial virus (RSV) in high-risk infants. [11]", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction. Over the years, passive immunization against many viral diseases was achieved by administering polyclonal sera obtained from convalescent human donors or animals. However, polyclonal antibody preparations are increasingly being replaced by monoclonal antibodies by virtue of their favorable safety profile and target specificity when used in different viral diseases. [10] Palivizumab was the first antiviral monoclonal antibody approved by the US Food and Drug Administration (FDA) for prophylaxis of respiratory syncytial virus (RSV) in high-risk infants. [11]"}
{"id": "article-133043_10", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction", "content": "Over the years, significant developments in antibody engineering, improved understanding of the biology of viruses, and the direct and indirect effect of monoclonal antibodies on viral infections have resulted in the development of many novel monoclonal antibodies. Like other antiviral drugs, monoclonal antibodies, when used as antiviral agents, are also susceptible to developing resistance as a result of alterations in the viral genome which can alter the pathogenic potential of the virus resulting in the emergence of viral escape mutants, which may render the virus-resistant to a specific monoclonal antibody.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction. Over the years, significant developments in antibody engineering, improved understanding of the biology of viruses, and the direct and indirect effect of monoclonal antibodies on viral infections have resulted in the development of many novel monoclonal antibodies. Like other antiviral drugs, monoclonal antibodies, when used as antiviral agents, are also susceptible to developing resistance as a result of alterations in the viral genome which can alter the pathogenic potential of the virus resulting in the emergence of viral escape mutants, which may render the virus-resistant to a specific monoclonal antibody."}
{"id": "article-133043_11", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction", "content": "To counter this viral escape phenomenon, some monoclonal antibodies were used in combination to complement each other and prevent neutralization escape by targeting multiple viral epitopes. However, as new variants emerged, resistance to multiple previously authorized monoclonal antibodies was noted. Several mAbs had their authorizations revoked in January 2022 by the FDA, with sotrovimab remaining as the only authorized monoclonal antibody that retains its efficacy as the dominant circulating variant of concern, Omicron.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Introduction. To counter this viral escape phenomenon, some monoclonal antibodies were used in combination to complement each other and prevent neutralization escape by targeting multiple viral epitopes. However, as new variants emerged, resistance to multiple previously authorized monoclonal antibodies was noted. Several mAbs had their authorizations revoked in January 2022 by the FDA, with sotrovimab remaining as the only authorized monoclonal antibody that retains its efficacy as the dominant circulating variant of concern, Omicron."}
{"id": "article-133043_12", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Function", "content": "COVID -19 is an acute viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 primarily affects the respiratory system; however, it can affect other major organ systems as well. Initially, the focus of treatment was directed mainly towards hospitalized patients with COVID-19 illness. However, the clinical focus throughout the pandemic has expanded toward combatting this illness early on by reducing the viral load in patients with early disease, thus attempting to halt the disease progression. Monoclonal antibodies are considered a promising approach in managing non-hospitalized patients with mild to moderate COVID-19 who are at high risk of developing severe illness.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Function. COVID -19 is an acute viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 primarily affects the respiratory system; however, it can affect other major organ systems as well. Initially, the focus of treatment was directed mainly towards hospitalized patients with COVID-19 illness. However, the clinical focus throughout the pandemic has expanded toward combatting this illness early on by reducing the viral load in patients with early disease, thus attempting to halt the disease progression. Monoclonal antibodies are considered a promising approach in managing non-hospitalized patients with mild to moderate COVID-19 who are at high risk of developing severe illness."}
{"id": "article-133043_13", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Function -- Mechanism of Action of Monoclonal Antibodies Against SARS-CoV-2", "content": "The pathophysiology of COVID-19 is described by the entry of SARS-CoV-2, the causative virus, into the hosts' cells by binding the SARS-CoV-2 spike or S protein (S1) to the angiotensin-converting enzyme 2 (ACE2) receptors expressed abundantly on the respiratory epithelium, such as type II alveolar epithelial cells. This\u00a0viral entry is mediated by the receptor-binding domain (RBD) on the spike protein followed by priming of the spike protein (S2) by the host transmembrane serine protease 2 (TMPRSS2) that facilitates cell entry and subsequent viral replication. [12] Monoclonal antibodies prevent the viral attachment by binding to a non-overlapping epitope on the surface spike protein RBD of SARS-CoV-2 with high affinity, thereby blocking the binding of the virus to the human ACE2 receptor.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Function -- Mechanism of Action of Monoclonal Antibodies Against SARS-CoV-2. The pathophysiology of COVID-19 is described by the entry of SARS-CoV-2, the causative virus, into the hosts' cells by binding the SARS-CoV-2 spike or S protein (S1) to the angiotensin-converting enzyme 2 (ACE2) receptors expressed abundantly on the respiratory epithelium, such as type II alveolar epithelial cells. This\u00a0viral entry is mediated by the receptor-binding domain (RBD) on the spike protein followed by priming of the spike protein (S2) by the host transmembrane serine protease 2 (TMPRSS2) that facilitates cell entry and subsequent viral replication. [12] Monoclonal antibodies prevent the viral attachment by binding to a non-overlapping epitope on the surface spike protein RBD of SARS-CoV-2 with high affinity, thereby blocking the binding of the virus to the human ACE2 receptor."}
{"id": "article-133043_14", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Function -- Mechanism of Action of Monoclonal Antibodies Against SARS-CoV-2", "content": "Sotrovimab (VIR-7831): This is a\u00a0potent anti-spike neutralizing monoclonal antibody that demonstrated in vitro activity against all the four VOCs\u00a0Alpha (B.1.1.7),\u00a0Beta (B.1.351),\u00a0Gamma(P1),\u00a0and Delta (B.1.617.2). Results from a preplanned interim analysis (not yet peer-reviewed) of the multicenter, double-blind placebo-controlled Phase 3, COMET-ICE trial by Gupta et al. that evaluated the clinical efficacy and safety of\u00a0sotrovimab demonstrated that one\u00a0dose of sotrovimab (500 mg) reduced the risk of hospitalization or death by 85% in high-risk non-hospitalized patients with mild to moderate COVID-19 compared with those receiving placebo.\u00a0Sotrovimab\u00a0monotherapy was granted emergency use authorization from FDA in May 2021 for clinical use in non-hospitalized patients with mild to moderate COVID-19 who are at increased risk for developing severe disease and/or hospitalization.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Function -- Mechanism of Action of Monoclonal Antibodies Against SARS-CoV-2. Sotrovimab (VIR-7831): This is a\u00a0potent anti-spike neutralizing monoclonal antibody that demonstrated in vitro activity against all the four VOCs\u00a0Alpha (B.1.1.7),\u00a0Beta (B.1.351),\u00a0Gamma(P1),\u00a0and Delta (B.1.617.2). Results from a preplanned interim analysis (not yet peer-reviewed) of the multicenter, double-blind placebo-controlled Phase 3, COMET-ICE trial by Gupta et al. that evaluated the clinical efficacy and safety of\u00a0sotrovimab demonstrated that one\u00a0dose of sotrovimab (500 mg) reduced the risk of hospitalization or death by 85% in high-risk non-hospitalized patients with mild to moderate COVID-19 compared with those receiving placebo.\u00a0Sotrovimab\u00a0monotherapy was granted emergency use authorization from FDA in May 2021 for clinical use in non-hospitalized patients with mild to moderate COVID-19 who are at increased risk for developing severe disease and/or hospitalization."}
{"id": "article-133043_15", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities", "content": "Disparities of rural and underserved healthcare go even further than just patient demographics and supply chain disruption. The COVID-19 pandemic has led to a\u00a0swift increase in virtual connections the world over. Removal of interpersonal physical contact has been a primary and effective approach to minimize transmission of COVID-19.\u00a0The spatial or social distancing approach has led to virtual connection\u00a0as the preferred method of meeting for\u00a0businesses, with many workers choosing to work remotely and many companies choosing to meet virtually. Remote work does not equate to a specific distance but rather refers to a site that is not the traditional office or worksite.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities. Disparities of rural and underserved healthcare go even further than just patient demographics and supply chain disruption. The COVID-19 pandemic has led to a\u00a0swift increase in virtual connections the world over. Removal of interpersonal physical contact has been a primary and effective approach to minimize transmission of COVID-19.\u00a0The spatial or social distancing approach has led to virtual connection\u00a0as the preferred method of meeting for\u00a0businesses, with many workers choosing to work remotely and many companies choosing to meet virtually. Remote work does not equate to a specific distance but rather refers to a site that is not the traditional office or worksite."}
{"id": "article-133043_16", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities", "content": "Telehealth systems have also been slowly implemented for many years and are helping to provide access for many patients unable to visit a traditional medical clinic for evaluation. Rural and underserved areas\u00a0can be severely limited in providing timely, stable, and uninterrupted telehealth access. The existing grid and infrastructure\u00a0often cannot provide high-speed network access in a reliable, consistent manner, or network access is simply unavailable. [13]", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities. Telehealth systems have also been slowly implemented for many years and are helping to provide access for many patients unable to visit a traditional medical clinic for evaluation. Rural and underserved areas\u00a0can be severely limited in providing timely, stable, and uninterrupted telehealth access. The existing grid and infrastructure\u00a0often cannot provide high-speed network access in a reliable, consistent manner, or network access is simply unavailable. [13]"}
{"id": "article-133043_17", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities", "content": "Local health departments continue expansion as technology becomes available and infrastructure is built. These same rural and underserved local health departments rely more on state and federal funding.\u00a0Unfortunately, this reliance on state and federal funding is vulnerable to state and federal policy change following local, regional, and federal election cycles. Recently several elected officials in states with significant rural populations have highlighted what was termed the \"Netflix standard,\" meaning that if residents can watch their favorite football team or Netflix on-demand in their homes, then we should be able to connect these same residents with healthcare providers. Further complicating the issue of funding is that many times a locale's public health funding is determined by an area's overall wealth and tax base, with rural areas generally lacking a significant tax base as the population density is low and/or much of the land is designated farmland with subsequent tax relief for property in the agricultural designation.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities. Local health departments continue expansion as technology becomes available and infrastructure is built. These same rural and underserved local health departments rely more on state and federal funding.\u00a0Unfortunately, this reliance on state and federal funding is vulnerable to state and federal policy change following local, regional, and federal election cycles. Recently several elected officials in states with significant rural populations have highlighted what was termed the \"Netflix standard,\" meaning that if residents can watch their favorite football team or Netflix on-demand in their homes, then we should be able to connect these same residents with healthcare providers. Further complicating the issue of funding is that many times a locale's public health funding is determined by an area's overall wealth and tax base, with rural areas generally lacking a significant tax base as the population density is low and/or much of the land is designated farmland with subsequent tax relief for property in the agricultural designation."}
{"id": "article-133043_18", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities", "content": "In rural areas, the crisis of the COVID-19 pandemic has been exacerbated by the generally poor patient demographics, as discussed. Residents of these areas have a higher prevalence of comorbidities such as hypertension, obesity, diabetes, and chronic lower respiratory diseases\u2014all of which increase their risk of death from COVID-19. With less funding\u00a0and staffing, a sicker general population, and, often, a larger geographical area in which to provide services, rural health systems are often not equipped nor staffed to deal with the extreme demands of a global pandemic. COVID-19 has highlighted many areas of\u00a0inequity and several fundamental flaws in how rural public health is funded and delivered.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities. In rural areas, the crisis of the COVID-19 pandemic has been exacerbated by the generally poor patient demographics, as discussed. Residents of these areas have a higher prevalence of comorbidities such as hypertension, obesity, diabetes, and chronic lower respiratory diseases\u2014all of which increase their risk of death from COVID-19. With less funding\u00a0and staffing, a sicker general population, and, often, a larger geographical area in which to provide services, rural health systems are often not equipped nor staffed to deal with the extreme demands of a global pandemic. COVID-19 has highlighted many areas of\u00a0inequity and several fundamental flaws in how rural public health is funded and delivered."}
{"id": "article-133043_19", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities", "content": "Perhaps as germane to the other disparities of rural and underserved communities is the disparate educational levels of the people living in\u00a0these areas. According to the department of education, in 2019, 39% of\u00a0residents described as living in an urban community\u00a0had attained a college degree of bachelor's equivalent versus 21% for those living in rural areas. Further, median household income was 25% higher for those living in urban areas.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities. Perhaps as germane to the other disparities of rural and underserved communities is the disparate educational levels of the people living in\u00a0these areas. According to the department of education, in 2019, 39% of\u00a0residents described as living in an urban community\u00a0had attained a college degree of bachelor's equivalent versus 21% for those living in rural areas. Further, median household income was 25% higher for those living in urban areas."}
{"id": "article-133043_20", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities", "content": "And, As the cost of education continues to rise, those living in more urban areas are able to partially mitigate higher educational costs by living at home. With\u00a0geographically favorable\u00a0access to many colleges and universities, the cost is even further defrayed. Compared to rural counterparts who often have to travel non-commutable distances and live on/near campus, the overall cost of attendance of higher education can be a significant hurdle for rural students.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities. And, As the cost of education continues to rise, those living in more urban areas are able to partially mitigate higher educational costs by living at home. With\u00a0geographically favorable\u00a0access to many colleges and universities, the cost is even further defrayed. Compared to rural counterparts who often have to travel non-commutable distances and live on/near campus, the overall cost of attendance of higher education can be a significant hurdle for rural students."}
{"id": "article-133043_21", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities", "content": "Overall, decreased rural\u00a0educational levels are also associated with a reduced understanding of fundamental physical, mental and sexual health principles and the benefits of healthy food choices and regular physical activity. Succinctly, health literacy is often lacking in these vulnerable populations, contributing to the vicious cycle of poor outcomes associated with public health crises and the COVID-19 pandemic.\u00a0Educational limitations continue to limit our vulnerable population's ability to gain a substantive understanding of vaccination benefits and monoclonal antibody use, further challenging rural communities in addressing the COVID-19 pandemic. Additional elements contributing to the disparate rural and underserved health problems identified include:", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities. Overall, decreased rural\u00a0educational levels are also associated with a reduced understanding of fundamental physical, mental and sexual health principles and the benefits of healthy food choices and regular physical activity. Succinctly, health literacy is often lacking in these vulnerable populations, contributing to the vicious cycle of poor outcomes associated with public health crises and the COVID-19 pandemic.\u00a0Educational limitations continue to limit our vulnerable population's ability to gain a substantive understanding of vaccination benefits and monoclonal antibody use, further challenging rural communities in addressing the COVID-19 pandemic. Additional elements contributing to the disparate rural and underserved health problems identified include:"}
{"id": "article-133043_22", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities", "content": "Declining population Economic stagnation Provider shortages A disproportionate number of elderly residents A disproportionate number of impoverished residents Significant numbers of\u00a0un/underinsured residents Higher rates of chronic illness", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities. Declining population Economic stagnation Provider shortages A disproportionate number of elderly residents A disproportionate number of impoverished residents Significant numbers of\u00a0un/underinsured residents Higher rates of chronic illness"}
{"id": "article-133043_23", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities", "content": "Simply put, the less healthy\u00a0the affected population, the more likely SARS COV-2 is to have fatal consequences.\u00a0Additionally, with a\u00a0weaker or less developed health system, the more difficult viral containment becomes.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities. Simply put, the less healthy\u00a0the affected population, the more likely SARS COV-2 is to have fatal consequences.\u00a0Additionally, with a\u00a0weaker or less developed health system, the more difficult viral containment becomes."}
{"id": "article-133043_24", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities", "content": "Conceivably though, healthcare costs may still be the most significant issue\u00a0rural and underserved residents face with a general lack of public health care in these communities. Even with the passage of the Patient Protection & Affordable Care Act, 30 million US residents lacked health insurance in the first half of 2020 , according  to estimates from the National Health Interview Survey (NHIS). The US Census estimates that uninsured rates of residents in rural or primarily rural\u00a0counties\u00a0outpace  urban areas by several percentage points. [14] Patients living in rural areas are disproportionately affected by regulatory and reimbursement changes to Medicare and Medicaid. Therefore, state and federal legislative actions are needed to offset healthcare costs for rural, impoverished residents.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities. Conceivably though, healthcare costs may still be the most significant issue\u00a0rural and underserved residents face with a general lack of public health care in these communities. Even with the passage of the Patient Protection & Affordable Care Act, 30 million US residents lacked health insurance in the first half of 2020 , according  to estimates from the National Health Interview Survey (NHIS). The US Census estimates that uninsured rates of residents in rural or primarily rural\u00a0counties\u00a0outpace  urban areas by several percentage points. [14] Patients living in rural areas are disproportionately affected by regulatory and reimbursement changes to Medicare and Medicaid. Therefore, state and federal legislative actions are needed to offset healthcare costs for rural, impoverished residents."}
{"id": "article-133043_25", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities", "content": "Secondarily, there is growing concern that many hospitals, in particular rural hospitals, may not have the financial reserves to remain fiscally viable. As of this writing, more than 100 rural hospitals have closed since 2010, with over 400 more hospitals at risk of closure. [15] Most rural hospitals rely on high-profit elective services\u00a0to provide financial stability. With the COVID-19 pandemic, many hospitals have had to cancel profitable services to provide care for the surge in COVID-19 affected patients. Rural hospitals are at greater risk of closure as operating financial margins are much smaller in these communities. A single rural hospital closure\u00a0could affect a wide catch net of residents. As shown, when these rural hospitals close, the physician workforce also leaves the area, further exacerbating the problem of delivering care in these vulnerable communities and further causing more local economic damage as associated supporting services are simply just not utilized to the same level. [16] [17]", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities. Secondarily, there is growing concern that many hospitals, in particular rural hospitals, may not have the financial reserves to remain fiscally viable. As of this writing, more than 100 rural hospitals have closed since 2010, with over 400 more hospitals at risk of closure. [15] Most rural hospitals rely on high-profit elective services\u00a0to provide financial stability. With the COVID-19 pandemic, many hospitals have had to cancel profitable services to provide care for the surge in COVID-19 affected patients. Rural hospitals are at greater risk of closure as operating financial margins are much smaller in these communities. A single rural hospital closure\u00a0could affect a wide catch net of residents. As shown, when these rural hospitals close, the physician workforce also leaves the area, further exacerbating the problem of delivering care in these vulnerable communities and further causing more local economic damage as associated supporting services are simply just not utilized to the same level. [16] [17]"}
{"id": "article-133043_26", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities", "content": "Even at baseline, rural areas have a much more significant\u00a0shortage of subspecialist physicians, including critical care trained clinicians to staff intensive care units. Additionally,\u00a0The Patient Protection & Affordable Care Act (PPACA) of 2010 drastically\u00a0reshaped\u00a0healthcare delivery in the United States. The spirit of providing healthcare to all residents in the United States was the driving force for the passage of the PPACA. As has been studied, there have been some unintended consequences of\u00a0Hospital Value-Based Purchasing (HVBP) and\u00a0the Hospital Readmission Reduction Program (HRRP) sections of the PPACA. For instance, as has well been established, rural resident demographics fall in several high-risk categories, and those vulnerable patients have a higher likelihood of morbidity and subsequent hospital readmission for their chronic high-risk disease. All hospitals\u00a0are financially penalized under the HRRP; however, the effect on rural hospitals\u00a0is greater, given the already slim operating financial margins. The Centers for Medicare and Medicaid Services (CMS) has implemented programs to monitor quality\u00a0with the\u00a0goal of quality driving improvement in care.\u00a0However, many of these programs have some blind spots when applied to rural areas.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Rural and Underserved Area Disparities. Even at baseline, rural areas have a much more significant\u00a0shortage of subspecialist physicians, including critical care trained clinicians to staff intensive care units. Additionally,\u00a0The Patient Protection & Affordable Care Act (PPACA) of 2010 drastically\u00a0reshaped\u00a0healthcare delivery in the United States. The spirit of providing healthcare to all residents in the United States was the driving force for the passage of the PPACA. As has been studied, there have been some unintended consequences of\u00a0Hospital Value-Based Purchasing (HVBP) and\u00a0the Hospital Readmission Reduction Program (HRRP) sections of the PPACA. For instance, as has well been established, rural resident demographics fall in several high-risk categories, and those vulnerable patients have a higher likelihood of morbidity and subsequent hospital readmission for their chronic high-risk disease. All hospitals\u00a0are financially penalized under the HRRP; however, the effect on rural hospitals\u00a0is greater, given the already slim operating financial margins. The Centers for Medicare and Medicaid Services (CMS) has implemented programs to monitor quality\u00a0with the\u00a0goal of quality driving improvement in care.\u00a0However, many of these programs have some blind spots when applied to rural areas."}
{"id": "article-133043_27", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Concerns With Monoclonal Antibody Use", "content": "Although generally well-tolerated, monoclonal antibody administration carries a\u00a0risk of immune-mediated reactions, including anaphylaxis, serum sickness, and antibody generation. Besides these immune-mediated reactions, the adverse effects of monoclonal antibodies are also related to their specific targets and are largely unknown due to the limited availability of published literature. Safety data from clinical trials evaluating monoclonal antibodies reported are summarized below. The most frequently reported adverse effects with the use of sotrovimab include infusion-related hypersensitivity reactions, rash, and\u00a0diarrhea. Clinical worsening of COVID-19 after monoclonal antibody administration may include but is not limited to fever, fatigue, hypoxia or increased respiratory difficulty, arrhythmias, and altered mental status.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Concerns With Monoclonal Antibody Use. Although generally well-tolerated, monoclonal antibody administration carries a\u00a0risk of immune-mediated reactions, including anaphylaxis, serum sickness, and antibody generation. Besides these immune-mediated reactions, the adverse effects of monoclonal antibodies are also related to their specific targets and are largely unknown due to the limited availability of published literature. Safety data from clinical trials evaluating monoclonal antibodies reported are summarized below. The most frequently reported adverse effects with the use of sotrovimab include infusion-related hypersensitivity reactions, rash, and\u00a0diarrhea. Clinical worsening of COVID-19 after monoclonal antibody administration may include but is not limited to fever, fatigue, hypoxia or increased respiratory difficulty, arrhythmias, and altered mental status."}
{"id": "article-133043_28", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Concerns With Monoclonal Antibody Use", "content": "Further, in instances where a patient may experience an adverse side effect, the likelihood of advanced subspecialty care or intensive care in rural areas would also be lacking. As the COVID-19 pandemic runs its course, we must use this opportunity to address public health disparities\u00a0for our underserved and remote communities. This approach will include audience-appropriate health education, developing clinician-patient relationships in these communities, and addressing concerns and fears, whether real or imagined, in a compassionate and caring manner. Developing relationships with community leaders who can assist with outreach and education is another potential way to address the hesitancy to accept monoclonal antibody therapy in these communities.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Issues of Concern -- Concerns With Monoclonal Antibody Use. Further, in instances where a patient may experience an adverse side effect, the likelihood of advanced subspecialty care or intensive care in rural areas would also be lacking. As the COVID-19 pandemic runs its course, we must use this opportunity to address public health disparities\u00a0for our underserved and remote communities. This approach will include audience-appropriate health education, developing clinician-patient relationships in these communities, and addressing concerns and fears, whether real or imagined, in a compassionate and caring manner. Developing relationships with community leaders who can assist with outreach and education is another potential way to address the hesitancy to accept monoclonal antibody therapy in these communities."}
{"id": "article-133043_29", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Clinical Significance", "content": "As per the Fact SheetS for Healthcare Providers provided by the US FDA on granting emergency use authorization (EUA) for the use of sotrovimab, adult and pediatric patients with mild to moderate COVID-19 illness are considered to be at high risk\u00a0if they meet at least\u00a0one of the following criteria:", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Clinical Significance. As per the Fact SheetS for Healthcare Providers provided by the US FDA on granting emergency use authorization (EUA) for the use of sotrovimab, adult and pediatric patients with mild to moderate COVID-19 illness are considered to be at high risk\u00a0if they meet at least\u00a0one of the following criteria:"}
{"id": "article-133043_30", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Clinical Significance", "content": "\u2265 65 years of age Have chronic kidney disease (CKD) Pregnant women Have underlying diabetes mellitus (DM) Have underlying immunosuppressive disease Are currently on immunosuppressive therapy Have a body mass index (BMI) \u2265 of 35 kg/m^2 Cardiovascular disease\u00a0or\u00a0hypertension\u00a0or  COPD/other chronic respiratory diseases Aged between 12 to 17 years\u00a0and  have a BMI \u2265 85 percentile for that age and gender-based on CDC growth charts, OR Have sickle cell disease,\u00a0or Have congenital or acquired heart disease,\u00a0or Have neurodevelopmental disorders,\u00a0or Have dependence on a medical-related technology device (e.g., tracheostomy, gastrostomy, or positive pressure ventilation unrelated to COVID-19,\u00a0or Have underlying asthma, reactive airway, or chronic respiratory disease that requires daily medication for control.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Clinical Significance. \u2265 65 years of age Have chronic kidney disease (CKD) Pregnant women Have underlying diabetes mellitus (DM) Have underlying immunosuppressive disease Are currently on immunosuppressive therapy Have a body mass index (BMI) \u2265 of 35 kg/m^2 Cardiovascular disease\u00a0or\u00a0hypertension\u00a0or  COPD/other chronic respiratory diseases Aged between 12 to 17 years\u00a0and  have a BMI \u2265 85 percentile for that age and gender-based on CDC growth charts, OR Have sickle cell disease,\u00a0or Have congenital or acquired heart disease,\u00a0or Have neurodevelopmental disorders,\u00a0or Have dependence on a medical-related technology device (e.g., tracheostomy, gastrostomy, or positive pressure ventilation unrelated to COVID-19,\u00a0or Have underlying asthma, reactive airway, or chronic respiratory disease that requires daily medication for control."}
{"id": "article-133043_31", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Clinical Significance", "content": "The authorized dosage under the FDA issued EUA is\u00a0500 mg of sotrovimab by IV infusion over 30 minutes\u00a0in adults and pediatric patients (12 years of age and older weighing at least 40 kgs) who have a positive SARS-CoV-2 test and who had symptoms for ten days or less and are at high risk for progression to severe COVID-19 disease", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Clinical Significance. The authorized dosage under the FDA issued EUA is\u00a0500 mg of sotrovimab by IV infusion over 30 minutes\u00a0in adults and pediatric patients (12 years of age and older weighing at least 40 kgs) who have a positive SARS-CoV-2 test and who had symptoms for ten days or less and are at high risk for progression to severe COVID-19 disease"}
{"id": "article-133043_32", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Clinical Significance", "content": "Based on the fact sheet by the FDA EUA sotrovimab is not authorized for use in patients hospitalized with COVID-19,  or\u00a0who require supplemental oxygen therapy due to COVID-19,\u00a0or\u00a0who require increasing baseline oxygen therapy due to COVID-19 in those who were previously on chronic oxygen therapy at baseline due to non-COVID-19 related comorbidity. It must not be administered to patients with known hypersensitivity to sotrovimab. The FDA also cautions against the use of sotrovimab in hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation as it may be associated with worse clinical outcomes.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Clinical Significance. Based on the fact sheet by the FDA EUA sotrovimab is not authorized for use in patients hospitalized with COVID-19,  or\u00a0who require supplemental oxygen therapy due to COVID-19,\u00a0or\u00a0who require increasing baseline oxygen therapy due to COVID-19 in those who were previously on chronic oxygen therapy at baseline due to non-COVID-19 related comorbidity. It must not be administered to patients with known hypersensitivity to sotrovimab. The FDA also cautions against the use of sotrovimab in hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation as it may be associated with worse clinical outcomes."}
{"id": "article-133043_33", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Clinical Significance", "content": "Patients treated with monoclonal antibody therapies should continue self-isolation measures and follow infection control measures such as wearing masks, practicing social distancing, cleaning and disinfecting surfaces and washing hands frequently according to CDC guidelines.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Clinical Significance. Patients treated with monoclonal antibody therapies should continue self-isolation measures and follow infection control measures such as wearing masks, practicing social distancing, cleaning and disinfecting surfaces and washing hands frequently according to CDC guidelines."}
{"id": "article-133043_34", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Enhancing Healthcare Team Outcomes", "content": "Coronavirus disease 2019 (COVID-19), the illness caused by SARS-CoV-2, has had a crippling effect on healthcare systems and economies worldwide.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Enhancing Healthcare Team Outcomes. Coronavirus disease 2019 (COVID-19), the illness caused by SARS-CoV-2, has had a crippling effect on healthcare systems and economies worldwide."}
{"id": "article-133043_35", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Enhancing Healthcare Team Outcomes", "content": "The emergency authorization for clinical use of monoclonal therapies in combatting COVID-19 appears promising.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Enhancing Healthcare Team Outcomes. The emergency authorization for clinical use of monoclonal therapies in combatting COVID-19 appears promising."}
{"id": "article-133043_36", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Enhancing Healthcare Team Outcomes", "content": "Limited published data exist regarding the adverse effects and drug-drug interactions with these therapies. Hence its clinical use in patients with COVID-19 illness presenting to the emergency department (ED) who do not require hospitalization but are at high risk of developing severe illness requires an interprofessional team that includes ED physicians, nurses, and pharmacists; they should be aware of the mechanism of action of these therapies, reported potential side effects, drug-drug interactions, and recommended doses.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Enhancing Healthcare Team Outcomes. Limited published data exist regarding the adverse effects and drug-drug interactions with these therapies. Hence its clinical use in patients with COVID-19 illness presenting to the emergency department (ED) who do not require hospitalization but are at high risk of developing severe illness requires an interprofessional team that includes ED physicians, nurses, and pharmacists; they should be aware of the mechanism of action of these therapies, reported potential side effects, drug-drug interactions, and recommended doses."}
{"id": "article-133043_37", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Enhancing Healthcare Team Outcomes", "content": "All patients should receive the fact sheet issued by the US FDA about the monoclonal antibody cocktail before receiving the drug.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Enhancing Healthcare Team Outcomes. All patients should receive the fact sheet issued by the US FDA about the monoclonal antibody cocktail before receiving the drug."}
{"id": "article-133043_38", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Enhancing Healthcare Team Outcomes", "content": "Considering monoclonal antibodies are commonly associated with infusion-related reactions, the patient should be monitored closely in the emergency department during the infusion and at least 1\u00a0to 2 hours after the infusion is complete.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Enhancing Healthcare Team Outcomes. Considering monoclonal antibodies are commonly associated with infusion-related reactions, the patient should be monitored closely in the emergency department during the infusion and at least 1\u00a0to 2 hours after the infusion is complete."}
{"id": "article-133043_39", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Enhancing Healthcare Team Outcomes", "content": "There should be close communication between the ordering ED physician, other clinicians, the pharmacist, and the ED nurse.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Enhancing Healthcare Team Outcomes. There should be close communication between the ordering ED physician, other clinicians, the pharmacist, and the ED nurse."}
{"id": "article-133043_40", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Enhancing Healthcare Team Outcomes", "content": "Such a holistic approach would lead to the early identification of potential side effects and drug-drug interactions associated with these drugs.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Enhancing Healthcare Team Outcomes. Such a holistic approach would lead to the early identification of potential side effects and drug-drug interactions associated with these drugs."}
{"id": "article-133043_41", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Enhancing Healthcare Team Outcomes", "content": "Lastly, outpatient clinics and healthcare communities should have a plan in place to triage moderate and high-risk patients for additional therapy, such as monoclonal antibodies in the emergency department if clinically indicated.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Enhancing Healthcare Team Outcomes. Lastly, outpatient clinics and healthcare communities should have a plan in place to triage moderate and high-risk patients for additional therapy, such as monoclonal antibodies in the emergency department if clinically indicated."}
{"id": "article-133043_42", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "According to the CDC, approximately 60 million, or 1 in 5, Americans live in rural or underserved areas of the United States. Every rural and underserved area is as unique as the residents that inhabit those areas, and unfortunately, no blanket strategy can be applied to every situation or community. Continued innovation, modernization, and original thought will be needed to confront the challenges in delivering effective, goal-directed healthcare to vulnerable populations. Many times, communities have disaster plans in place, and reference to these plans would be the first step in developing a rural public health referral network. Reference to the local disaster plan will answer many initial questions posed. However, existing disaster plans are usually designed with a focus on natural disasters or infrastructure breakdowns.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions. According to the CDC, approximately 60 million, or 1 in 5, Americans live in rural or underserved areas of the United States. Every rural and underserved area is as unique as the residents that inhabit those areas, and unfortunately, no blanket strategy can be applied to every situation or community. Continued innovation, modernization, and original thought will be needed to confront the challenges in delivering effective, goal-directed healthcare to vulnerable populations. Many times, communities have disaster plans in place, and reference to these plans would be the first step in developing a rural public health referral network. Reference to the local disaster plan will answer many initial questions posed. However, existing disaster plans are usually designed with a focus on natural disasters or infrastructure breakdowns."}
{"id": "article-133043_43", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "The COVID-19 pandemic has highlighted that these plans should be reviewed to include public health crises as well. As\u00a0has been established\u00a0objectively, the current pandemic has caused more cumulative death and economic damage than the entirety of the last decade of natural disasters. Each community will have its own disaster plan review frequency; however, an annual review would be prudent as technology advances rapidly, and systems are changing at a\u00a0torrid\u00a0pace. Population shifts across the country have been common since the outset of the current COVID-19 pandemic, and plan review should consider the shifting local demographics and population density.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions. The COVID-19 pandemic has highlighted that these plans should be reviewed to include public health crises as well. As\u00a0has been established\u00a0objectively, the current pandemic has caused more cumulative death and economic damage than the entirety of the last decade of natural disasters. Each community will have its own disaster plan review frequency; however, an annual review would be prudent as technology advances rapidly, and systems are changing at a\u00a0torrid\u00a0pace. Population shifts across the country have been common since the outset of the current COVID-19 pandemic, and plan review should consider the shifting local demographics and population density."}
{"id": "article-133043_44", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "The following are some basic yet broad\u00a0ideas to assist in establishing referral systems\u00a0in rural and underserved areas. These suggestions are the authors' opinion and are not comprehensive nor exclusive to this article and are meant as a starting point in assessing local referral networks and, in particular, referrals for monoclonal antibody treatments.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions. The following are some basic yet broad\u00a0ideas to assist in establishing referral systems\u00a0in rural and underserved areas. These suggestions are the authors' opinion and are not comprehensive nor exclusive to this article and are meant as a starting point in assessing local referral networks and, in particular, referrals for monoclonal antibody treatments."}
{"id": "article-133043_45", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "A first step would be to assess existing local facilities with the ability to provide monoclonal antibody treatment that is adequately staffed with trained nurses and medical professionals. If no such facility exists, what is the next closest\u00a0facility? Then, a plan can be developed to refer and, if needed, mobilize local residents to these facilities. The following is a suggested framework to develop a logical, sensible plan to establish a referral system for high-risk residents of rural or underserved to get monoclonal antibody treatment.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions. A first step would be to assess existing local facilities with the ability to provide monoclonal antibody treatment that is adequately staffed with trained nurses and medical professionals. If no such facility exists, what is the next closest\u00a0facility? Then, a plan can be developed to refer and, if needed, mobilize local residents to these facilities. The following is a suggested framework to develop a logical, sensible plan to establish a referral system for high-risk residents of rural or underserved to get monoclonal antibody treatment."}
{"id": "article-133043_46", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "Look\u00a0at the local public health problem from a\u00a0broad\u00a0lens with respect to the local community.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions. Look\u00a0at the local public health problem from a\u00a0broad\u00a0lens with respect to the local community."}
{"id": "article-133043_47", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "Each local community is different. Consider the unique challenges of the local community, including basic infrastructure. Work to identify why the community is facing challenges. Is\u00a0public transit available? Is local ride-sharing available? Would\u00a0partnership with a ride-sharing system make sense?", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions. Each local community is different. Consider the unique challenges of the local community, including basic infrastructure. Work to identify why the community is facing challenges. Is\u00a0public transit available? Is local ride-sharing available? Would\u00a0partnership with a ride-sharing system make sense?"}
{"id": "article-133043_48", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "Compile a database of available resources and projected needs.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions. Compile a database of available resources and projected needs."}
{"id": "article-133043_49", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "Human resource needs. Who are the local subject matter experts? Local clinicians Local engineers Others with expertise in respect to the issue at hand Who will keep medical records? How will the integrity and confidentiality of the records be ensured? Will the private sector be involved? If so, who? Have these stakeholders been contacted and brought into decision-making? Resident needs Educational content for residents to\u00a0promote understanding of COVID-19 disease, vaccinations for COVID-19, and monoclonal antibody therapy Responsible social media and local municipal informational webpages Engagement with local civic and religious leaders with reach to assist with education and information distribution Operational Needs With the COVID-19 Pandemic, PPE was an early need. Should stockpiles be considered for future use? How\u00a0might another public health crisis occur,\u00a0and in what form will it appear? Will food, transportation, water, etc.,\u00a0be needed? Storage facilities? Mobile operating centers? Mobile resource delivery?", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions. Human resource needs. Who are the local subject matter experts? Local clinicians Local engineers Others with expertise in respect to the issue at hand Who will keep medical records? How will the integrity and confidentiality of the records be ensured? Will the private sector be involved? If so, who? Have these stakeholders been contacted and brought into decision-making? Resident needs Educational content for residents to\u00a0promote understanding of COVID-19 disease, vaccinations for COVID-19, and monoclonal antibody therapy Responsible social media and local municipal informational webpages Engagement with local civic and religious leaders with reach to assist with education and information distribution Operational Needs With the COVID-19 Pandemic, PPE was an early need. Should stockpiles be considered for future use? How\u00a0might another public health crisis occur,\u00a0and in what form will it appear? Will food, transportation, water, etc.,\u00a0be needed? Storage facilities? Mobile operating centers? Mobile resource delivery?"}
{"id": "article-133043_50", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "Prioritization of goals .", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions. Prioritization of goals ."}
{"id": "article-133043_51", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "What is the overall goal of the plan?\u00a0Focus on a few specific overall goals rather than\u00a0a broad array of ideas. Align goals with resources availability. Is setting up telehealth access sensible if there is no or limited broadband available to the residents. Would setting up testing centers for COVID-19 be\u00a0practical just because tests are available, but no treatment facility exists?", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions. What is the overall goal of the plan?\u00a0Focus on a few specific overall goals rather than\u00a0a broad array of ideas. Align goals with resources availability. Is setting up telehealth access sensible if there is no or limited broadband available to the residents. Would setting up testing centers for COVID-19 be\u00a0practical just because tests are available, but no treatment facility exists?"}
{"id": "article-133043_52", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "Implementation policies that make sense for the local community Establishing public trust at the outset of any plan will increase the chances of public buy-in and successful implementation. A strong argument can be made that establishing public trust should be a continual and primary objective of all local civic organizations.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions. Implementation policies that make sense for the local community Establishing public trust at the outset of any plan will increase the chances of public buy-in and successful implementation. A strong argument can be made that establishing public trust should be a continual and primary objective of all local civic organizations."}
{"id": "article-133043_53", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "As always, an interprofessional team will likely be most effective in solving the community's unique challenges as each member will bring a different perspective to the table. This team\u00a0could include local civic leaders and members of larger organizations with reach, connection, and established trust within the community residents. Local clinicians, allied health providers, and nurses should be included in the problem-solving process concerning public health.\u00a0Efforts should also be explicitly made to ensure those residents that are the targets of the policy and all vulnerable populations are included in the decision-making process. Thorough, nonjudgemental, and collaborative communication will be key in not only meeting the challenges faced but also in making effective changes in a timely manner so that the local residents may benefit dynamically rather than at some non-explicit point in the future as well as making changes that are sensible and reflect actual needs rather than theoretical ideas of needs.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions. As always, an interprofessional team will likely be most effective in solving the community's unique challenges as each member will bring a different perspective to the table. This team\u00a0could include local civic leaders and members of larger organizations with reach, connection, and established trust within the community residents. Local clinicians, allied health providers, and nurses should be included in the problem-solving process concerning public health.\u00a0Efforts should also be explicitly made to ensure those residents that are the targets of the policy and all vulnerable populations are included in the decision-making process. Thorough, nonjudgemental, and collaborative communication will be key in not only meeting the challenges faced but also in making effective changes in a timely manner so that the local residents may benefit dynamically rather than at some non-explicit point in the future as well as making changes that are sensible and reflect actual needs rather than theoretical ideas of needs."}
{"id": "article-133043_54", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "Change in how healthcare is delivered will be met with skepticism, not all of which is unfounded. A large component of telehealth concern centers around the medicolegal and ethical aspects of healthcare delivery in this way. Practitioners cite concern with malpractice when practicing from \"afar.\" While there are models for teleradiology and tele-neurology that are widely practiced, one of the comforts of these subspecialties is that an actual practitioner is physically present with the patient to ensure the reliability of information gathering and physical exam findings. With the continued rollout of telehealth, safety measures will need to be considered to alleviate practitioner fears of malpractice and ensure the integrity of care. [18] [19] As telehealth secures a more prominent role in healthcare delivery, vigilance\u00a0is necessary to address ethical concerns and responsible technology use. Basic ethical tenants to consider are:", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions. Change in how healthcare is delivered will be met with skepticism, not all of which is unfounded. A large component of telehealth concern centers around the medicolegal and ethical aspects of healthcare delivery in this way. Practitioners cite concern with malpractice when practicing from \"afar.\" While there are models for teleradiology and tele-neurology that are widely practiced, one of the comforts of these subspecialties is that an actual practitioner is physically present with the patient to ensure the reliability of information gathering and physical exam findings. With the continued rollout of telehealth, safety measures will need to be considered to alleviate practitioner fears of malpractice and ensure the integrity of care. [18] [19] As telehealth secures a more prominent role in healthcare delivery, vigilance\u00a0is necessary to address ethical concerns and responsible technology use. Basic ethical tenants to consider are:"}
{"id": "article-133043_55", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "Beneficence - providing services that generally promote good\u00a0for the individual and community Non-Maleficence - doing no harm to the individual or community Justice - treating every situation/resident equally Autonomy - allowing\u00a0residents their own choice in care", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions. Beneficence - providing services that generally promote good\u00a0for the individual and community Non-Maleficence - doing no harm to the individual or community Justice - treating every situation/resident equally Autonomy - allowing\u00a0residents their own choice in care"}
{"id": "article-133043_56", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "Consider for a moment an elderly patient who has been contacted via telehealth. The practitioner determines that this patient would benefit from monoclonal antibody therapy. The patient has agreed that treatment may be helpful and wishes to proceed. However, the patient has no transportation. In another scenario, a known more remote part of\u00a0the community has poor cellphone service and minimal high-speed internet. Yet, a few miles closer, these issues do not exist, and cell phone service is excellent. How would the gap be closed to provide services to both groups? Even more, would residents who are not adequately informed and educated about COVID-19 disease, vaccinations, and monoclonal antibody therapy, really be able to make a truly autonomous decision?", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions. Consider for a moment an elderly patient who has been contacted via telehealth. The practitioner determines that this patient would benefit from monoclonal antibody therapy. The patient has agreed that treatment may be helpful and wishes to proceed. However, the patient has no transportation. In another scenario, a known more remote part of\u00a0the community has poor cellphone service and minimal high-speed internet. Yet, a few miles closer, these issues do not exist, and cell phone service is excellent. How would the gap be closed to provide services to both groups? Even more, would residents who are not adequately informed and educated about COVID-19 disease, vaccinations, and monoclonal antibody therapy, really be able to make a truly autonomous decision?"}
{"id": "article-133043_57", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool", "content": "Objectively, the COVID-19 Community Vulnerability Index (CCVI) tool is designed after the CDC's Social Vulnerability index. [20] The Idea behind CCVI was to incorporate the latest evidence of COVID-19 risk factors, with data, and dozens of other indicators, into a single score for a population of interest, whether it is a city, county, or state. CCVI considers the seven following indicators when looking at a community's vulnerability index: Socioeconomic status Minority status and transportation Household and transportation Epidemiological factors Healthcare system factors High-risk environments Population density", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool. Objectively, the COVID-19 Community Vulnerability Index (CCVI) tool is designed after the CDC's Social Vulnerability index. [20] The Idea behind CCVI was to incorporate the latest evidence of COVID-19 risk factors, with data, and dozens of other indicators, into a single score for a population of interest, whether it is a city, county, or state. CCVI considers the seven following indicators when looking at a community's vulnerability index: Socioeconomic status Minority status and transportation Household and transportation Epidemiological factors Healthcare system factors High-risk environments Population density"}
{"id": "article-133043_58", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool", "content": "Each of the above themes has its own score of zero, the lowest vulnerability, and 1, the highest vulnerability. Based on these indicators, CCVI can predict why and where there would be worse health, social, and economic outcomes after COVID 19. CCVI offers information for local and state leaders to help understand where there are limited resources. This scoring system helps them identify these areas in need and where to focus interventions such as equipment for healthcare systems, quarantine accommodation, or support for rent payments depending on the community's vulnerability index.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool. Each of the above themes has its own score of zero, the lowest vulnerability, and 1, the highest vulnerability. Based on these indicators, CCVI can predict why and where there would be worse health, social, and economic outcomes after COVID 19. CCVI offers information for local and state leaders to help understand where there are limited resources. This scoring system helps them identify these areas in need and where to focus interventions such as equipment for healthcare systems, quarantine accommodation, or support for rent payments depending on the community's vulnerability index."}
{"id": "article-133043_59", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool", "content": "The action-oriented solution that CCVI offers allows\u00a0one\u00a0to identify the area of deficit, prepare a plan and address the gaps identified, respond with target-specific interventions and resources, and finally monitor the outcome of the response and how it impacts the vulnerability of the community. Each of the\u00a0seven indicators incorporated into CCVI has associated interventions that help reduce the community's vulnerability. Below are some listed interventions that could be taken when a deficit is identified in each underlying driver of vulnerability.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool. The action-oriented solution that CCVI offers allows\u00a0one\u00a0to identify the area of deficit, prepare a plan and address the gaps identified, respond with target-specific interventions and resources, and finally monitor the outcome of the response and how it impacts the vulnerability of the community. Each of the\u00a0seven indicators incorporated into CCVI has associated interventions that help reduce the community's vulnerability. Below are some listed interventions that could be taken when a deficit is identified in each underlying driver of vulnerability."}
{"id": "article-133043_60", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool", "content": "Socioeconomic Status Financial relief for lower-income bracket individuals Free\u00a0or low-cost testing and vaccines", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool. Socioeconomic Status Financial relief for lower-income bracket individuals Free\u00a0or low-cost testing and vaccines"}
{"id": "article-133043_61", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool", "content": "Minority Status and Transportation Tailor communication and channels for specific populations if needed", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool. Minority Status and Transportation Tailor communication and channels for specific populations if needed"}
{"id": "article-133043_62", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool", "content": "Household and Transportation Public-private partnerships for access to transportation for testing or healthcare Mobile testing and vaccine sites", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool. Household and Transportation Public-private partnerships for access to transportation for testing or healthcare Mobile testing and vaccine sites"}
{"id": "article-133043_63", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool", "content": "Epidemiological Factors Support stay at home with financial and food support of those at most risk Allow highly vulnerable individuals to avoid contaminated workspaces", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool. Epidemiological Factors Support stay at home with financial and food support of those at most risk Allow highly vulnerable individuals to avoid contaminated workspaces"}
{"id": "article-133043_64", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool", "content": "Healthcare System Factors Enact mobile or temporary emergency response facilities Local nonprofit and other community organizations to help fill gaps", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool. Healthcare System Factors Enact mobile or temporary emergency response facilities Local nonprofit and other community organizations to help fill gaps"}
{"id": "article-133043_65", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool", "content": "High-risk environments Prisons, Nursing homes Resources for testing, tracing, and isolation of cases Frequent Health inspections of conditions and employment conditions to avoid outbreaks Support self-isolation Continue rapid testing within these high-risk environments Limit capacities within these facilities.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool. High-risk environments Prisons, Nursing homes Resources for testing, tracing, and isolation of cases Frequent Health inspections of conditions and employment conditions to avoid outbreaks Support self-isolation Continue rapid testing within these high-risk environments Limit capacities within these facilities."}
{"id": "article-133043_66", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool", "content": "Population Density", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool. Population Density"}
{"id": "article-133043_67", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool", "content": "Mask mandates", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool. Mask mandates"}
{"id": "article-133043_68", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool", "content": "Public area capacity limits", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool. Public area capacity limits"}
{"id": "article-133043_69", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool", "content": "Minimize non-essential indoor events", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool. Minimize non-essential indoor events"}
{"id": "article-133043_70", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool", "content": "Lastly, the CCVI tool allows local and state leaders to identify areas of need and where to delegate resources. This tool also allows these leaders to continue to monitor and see how these changes and resources affect the community's vulnerability. Ultimately, each community\u00a0is vested in itself and will be the most likely to affect positive change locally; this is\u00a0especially true for rural areas as these communities are\u00a0smaller, closer-knit, and not as subject to the bureaucracy known to bog down effective change in larger communities.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool. Lastly, the CCVI tool allows local and state leaders to identify areas of need and where to delegate resources. This tool also allows these leaders to continue to monitor and see how these changes and resources affect the community's vulnerability. Ultimately, each community\u00a0is vested in itself and will be the most likely to affect positive change locally; this is\u00a0especially true for rural areas as these communities are\u00a0smaller, closer-knit, and not as subject to the bureaucracy known to bog down effective change in larger communities."}
{"id": "article-133043_71", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool", "content": "In conclusion, the\u00a0questions and ideas posed are not intended to be answers for any single community. Simply these questions and ideas are posed to generate thought and assist in starting the necessary conversations to develop a plan that will best suit\u00a0each local communities needs. As demonstrated, rural and underserved communities face\u00a0a multitude of\u00a0challenges, and no one-size-fits-all solution is available.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Nursing, Allied Health, and Interprofessional Team Interventions -- COVID-19 Community Vulnerability Index (CCVI) Tool. In conclusion, the\u00a0questions and ideas posed are not intended to be answers for any single community. Simply these questions and ideas are posed to generate thought and assist in starting the necessary conversations to develop a plan that will best suit\u00a0each local communities needs. As demonstrated, rural and underserved communities face\u00a0a multitude of\u00a0challenges, and no one-size-fits-all solution is available."}
{"id": "article-133043_72", "title": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived) -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}